Organon & Co. (OGN) compared with its closest peers (ALNY, BMRN, UTHR, AMRX, VTRS): P/E 17.3 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Alnylam Pharmaceuticals, BioMarin Pharmaceutical, United Therapeutics, Amneal Pharmaceuticals, Viatris, Royalty Pharma, Sarepta Therapeutics, PTC Therapeutics, Zoetis and Indivior Pharmaceuticals share Organon's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.53B | 108.0 |
| BioMarin Pharmaceutical Inc. (BMRN) | $12.91B | 176.9 |
| United Therapeutics Corporation (UTHR) | $21.77B | 16.6 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $5.71B | 36.3 |
| Viatris Inc. (VTRS) | $18.99B | -4.2 |
| Royalty Pharma plc (RPRX) | $34.13B | 41.3 |
| Sarepta Therapeutics, Inc. (SRPT) | $1.98B | -3.0 |
| PTC Therapeutics, Inc. (PTCT) | $5.83B | 9.8 |
| Zoetis Inc. (ZTS) | $32.59B | 12.3 |
| Indivior Pharmaceuticals Inc (INDV) | $4.35B | 12.7 |
| Stock P/E | 17.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -20.5% |
| vs Industry | 0.7% |
OGN overview · OGN earnings · OGN financials · OGN KPIs · OGN documents · OGN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.